SCHEMBL2926256

SCHEMBL2926256

Cc1c(C#N)c(Cl)nc(-c2ccc(F)cc2)c1-c1ccncc1C#N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.49
KDM1A O60341 1/20 0.42
ALDH1A1 P00352 4/20 0.40
MAPT P10636 3/20 0.40
MAPK13 O15264 1/20 0.40
GCGR P47871 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
MAPK14 Q16539 1/20 0.40
MAPK1 P28482 1/20 0.40
GAA P10253 3/20 0.40
KMT2A Q03164 2/20 0.40
HSD17B10 Q99714 1/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
SQOR Q9Y6N5 4/20 0.38
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931467 0.87 KDM4E (0.47) KDM4EALDH1A1MAPTMAPK13GCGR
SCHEMBL2926252 0.83 KDM4E (0.49) KDM4EKDM1AALDH1A1MAPTMAPK13
SCHEMBL2932221 0.78 RPS6KA3 (0.40) KDM4EKDM1AALDH1A1MAPK13GCGR
SCHEMBL6626450 0.73 RPS6KA3 (0.47) KDM4EALDH1A1MAPK13GCGRMAPK12
SCHEMBL2930459 0.69 RPS6KA3 (0.43) KDM4EALDH1A1MAPTMAPK13GCGR
SCHEMBL2931462 0.69 KDM4E (0.46) KDM4EALDH1A1MAPTMAPK13GCGR
SCHEMBL2932218 0.69 CNR1 (0.49) MAPK13GCGRMAPK12MAPK11MAPK14
SCHEMBL3990856 0.65 LRRK2 (0.54) KDM4ECYP1A2CYP2C9CYP2C19HPGD
SCHEMBL31133690 0.63 HTT (0.48) ALDH1A1KMT2AMEN1CYP1A2CYP2C9
SCHEMBL15638514 0.63 KDM4E (0.61) KDM4EKDM1AALDH1A1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 EP disclosed
WO-2004076450-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach Y Compañia S.A. (ES) 2004-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 KDM4E 3384/4885KDM1A 2646/4885ALDH1A1 789/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 KDM4E 3953/4885KDM1A 3581/4885ALDH1A1 1040/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 KDM4E 3953/4885KDM1A 3581/4885ALDH1A1 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.